3 results
Approved WMORecruiting
In 2013 the Boston Scientific VERCISE System has obtained regulatory approval for use in the European Union, CE mark was granted for the treatment of intractable primary and secondary dystonia.The objective of the study is to compile characteristics…
Approved WMORecruiting
To demonstrate safety and efficacy of Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DESin wide clinical use.
Approved WMORecruiting
The primary objectives of the study are to:Determine the OBD(s) and RP2D's) of BMF-219 monotherapy administered daily based on evaluation of all available PK/ PD, target engagement, safety, and tolerability data. Note that the OBD and RP2D may…